latest news2010 Annual Report - Complete 2010 Annual Report - Financials 2010 Annual Report - Editorial Full Year Statutory Accounts Preliminary Final Report Commentary on Results LAIV Launched in India Rights Issue Update Notification of under subscriptions Supplementary Prospectus Board Changes Broker Presentation BioDiem Prospectus 2010 Notice of General Meeting / Proxy Form / Independent Expert Reports Pandemic Influenza Vaccine Program Update Letter to Shareholders Appendix 3B Non-Renounceable Pro-Rata Rights Issue Prospectus Appendix 3B BDM Launches Non-Renounceable Rights Issue Half Yearly Results Half Year Report and Accounts Shareholder Update February 2010 Appendix 4C Quarterly Report BioDiem regains Japanese Rights Extension of Co-operative Research Development Agreement WHO issues a further sublicence of LAIV Appendix 4C Quarterly Report LAIV Proof of Concept Trial Results of AGM AGM Presentation Chairman's Address to Shareholders WHO Sub-licenses BDM's LAIV Technology Agreement with PATH for Prototype Pandemic Influenza Vaccine Completion of Phase I Clinical Trial Recruitment for LAIV Notice of Meeting & Proxy Form | Investor InformationASX Announcements Financial Results
| ASX Link
|